Ocugen, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ocugen, Inc. on March 17, 2022. The filing addresses corporate governance changes, specifically the departure of a director, the appointment of a new director, and the execution of an amended employment agreement for the Chief Accounting Officer.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses specific compensation and equity grant values:
- Director Equity Grant: Marna Whittington, Ph.D. received an initial option grant with a fair value of $285,000.
- Executive Compensation: Jessica Crespo (Chief Accounting Officer) received an annual base salary of $375,000 and a target annual bonus of at least 40% of base salary.
- Executive Equity Grants: Ms. Crespo received a stock option with a fair value of $225,000 and restricted stock units valued at $75,000.
Material Changes
The following material changes to the Board and executive team were reported:
- Director Departure: Manish Potti notified the Board on March 17, 2022, that he will not stand for re-election as a Class II director at the 2022 Annual Meeting. His departure is for personal reasons and not due to any disagreement with the Company.
- Board Expansion: The Board size was temporarily increased from seven to eight members. Marna Whittington, Ph.D. was appointed as a Class II director, effective March 21, 2022. The Board size is scheduled to decrease back to seven following the Annual Meeting.
- Executive Agreement: An amended and restated employment agreement was approved for Jessica Crespo, effective March 18, 2022.
Outlook, Risks, and Contingencies
The filing does not provide financial guidance or discuss operational risks. It notes that severance benefits for Ms. Crespo are contingent upon the execution of a release of claims. These benefits include 12 months of base salary and COBRA premiums upon termination without cause or for good reason, with additional lump-sum payments and immediate equity vesting if termination occurs near a change of control.
Investor Verification Checklist
- Verify the exact date of the 2022 Annual Meeting to confirm when Manish Potti's departure becomes effective.
- Review the full text of the amended employment agreement for Jessica Crespo to understand specific definitions of "without cause," "good reason," and "change of control."
- Confirm the vesting schedule details for the equity awards granted to Dr. Whittington and Ms. Crespo in subsequent periodic reports.
- Monitor the Board composition post-Annual Meeting to confirm the reduction to seven directors.